Status:
COMPLETED
Hematotoxicity in Maintenance Therapy of Children With Acute Lymphoblastic Leukemia
Lead Sponsor:
Indonesia University
Conditions:
Mercaptopurine Adverse Reaction
Leukemia, Lymphoblastic
Eligibility:
All Genders
1-18 years
Brief Summary
Subjects who are recruited in this study are LLA patient, who are treated for routine control to Cipto Mangunkusumo Hospital, who meet the inclusion criteria and do not meet the exclusion criteria.
Detailed Description
On the day of the control patient, (usually the patient is asked for routine control at week 3 on mercaptopurin) routine blood tests are performed. Patients and parents were given an explanation of th...
Eligibility Criteria
Inclusion
- Acute lymphoblastic leukemia (ALL) patients, 1 until 18 years old, male or female, who come to Cipto Mangunkusumo Hospital, Jakarta, Indonesia
- Received 6MP chemotherapy at least 1 month maintenance phase
- Received maintenance phase treatment regimen
- Willing to participate in research, signed informed consent and obtained parental consent to participate in research
Exclusion
- Patients are experiencing severe infections
- Patients receiving colony stimulating factor (CSF), allopurinol, mesalazine, olsalazine, and sulfasalazine
Key Trial Info
Start Date :
July 25 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 1 2018
Estimated Enrollment :
106 Patients enrolled
Trial Details
Trial ID
NCT03255668
Start Date
July 25 2017
End Date
November 1 2018
Last Update
November 20 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cipto Mangunkusomo hospital
Jakarta Pusat, Jakarta Special Capital Region, Indonesia, 10430